Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study

Identifieur interne : 004053 ( Main/Exploration ); précédent : 004052; suivant : 004054

Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study

Auteurs : Jau-Shin Lou [États-Unis] ; Greg Kearns [États-Unis] ; Theodore Benice [États-Unis] ; Barry Oken [États-Unis] ; Gary Sexton [États-Unis] ; John Nutt [États-Unis]

Source :

RBID : ISTEX:9F3A0B88BDBDA778663C8133C5FE3B60024071E5

Descripteurs français

English descriptors

Abstract

We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Visit 1 or 2 and participated in the following two studies: (1) Finger tapping. Twenty‐five PD patients used their index fingers to strike two keys 20 cm apart on a musical instrument digital interface (MIDI) keyboard. The slopes of the regression line of dwell time and movement time were used to assess the rate of fatigue development. (2) Force generation. Twelve PD patients contracted the wrist extensors maximally to obtain a baseline maximum voluntary contraction (BMVC) force. Then they repetitively contracted the wrist extensors at 50% of the BMVC for 7 seconds and rested for 3 seconds. An interval maximum voluntary contraction (IMVC) was measured every three repetitions. Fatigue was defined as an IMVC of less than 60% of the BMVC. The slope of the regression line of IMVC was used to assess the rate of force decline. These two studies were repeated 1 hour after carbidopa/levodopa (25/100) or placebo. Subjects filled out the Multidimensional Fatigue Inventory (MFI) at the beginning of the first visit. Results showed that the slope of dwell time decreased with levodopa but not with placebo (P = 0.004). The rate of force decline also decreased with levodopa but not with placebo (P = 0.01). The subscores in the dimension of physical fatigue in the MFI did not correlate with the rate changes in dwell time or the rate changes in force decline. We concluded that (1) levodopa improves physical fatigue in finger tapping and force generation, (2) physical fatigue in Parkinson's disease is at least partially related to dopamine deficiency, and (3) the MFI measures different aspects of physical fatigue compared with those measured by finger tapping and force generation. © 2003 Movement Disorder Society

Url:
DOI: 10.1002/mds.10505


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study</title>
<author>
<name sortKey="Lou, Jau Hin" sort="Lou, Jau Hin" uniqKey="Lou J" first="Jau-Shin" last="Lou">Jau-Shin Lou</name>
</author>
<author>
<name sortKey="Kearns, Greg" sort="Kearns, Greg" uniqKey="Kearns G" first="Greg" last="Kearns">Greg Kearns</name>
</author>
<author>
<name sortKey="Benice, Theodore" sort="Benice, Theodore" uniqKey="Benice T" first="Theodore" last="Benice">Theodore Benice</name>
</author>
<author>
<name sortKey="Oken, Barry" sort="Oken, Barry" uniqKey="Oken B" first="Barry" last="Oken">Barry Oken</name>
</author>
<author>
<name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
</author>
<author>
<name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9F3A0B88BDBDA778663C8133C5FE3B60024071E5</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10505</idno>
<idno type="url">https://api.istex.fr/document/9F3A0B88BDBDA778663C8133C5FE3B60024071E5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C55</idno>
<idno type="wicri:Area/Istex/Curation">000C55</idno>
<idno type="wicri:Area/Istex/Checkpoint">002983</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Lou J:levodopa:improves:physical</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14534913</idno>
<idno type="wicri:Area/PubMed/Corpus">003673</idno>
<idno type="wicri:Area/PubMed/Curation">003673</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003745</idno>
<idno type="wicri:Area/Ncbi/Merge">000B91</idno>
<idno type="wicri:Area/Ncbi/Curation">000B91</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B91</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Lou J:levodopa:improves:physical</idno>
<idno type="wicri:Area/Main/Merge">005C76</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0096078</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002356</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000965</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002419</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Lou J:levodopa:improves:physical</idno>
<idno type="wicri:Area/Main/Merge">005F65</idno>
<idno type="wicri:Area/Main/Curation">004053</idno>
<idno type="wicri:Area/Main/Exploration">004053</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study</title>
<author>
<name sortKey="Lou, Jau Hin" sort="Lou, Jau Hin" uniqKey="Lou J" first="Jau-Shin" last="Lou">Jau-Shin Lou</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
<placeName>
<region type="state">Oregon</region>
<settlement type="city">Portland</settlement>
</placeName>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
</affiliation>
</author>
<author>
<name sortKey="Kearns, Greg" sort="Kearns, Greg" uniqKey="Kearns G" first="Greg" last="Kearns">Greg Kearns</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
<placeName>
<region type="state">Oregon</region>
<settlement type="city">Portland</settlement>
</placeName>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
</affiliation>
</author>
<author>
<name sortKey="Benice, Theodore" sort="Benice, Theodore" uniqKey="Benice T" first="Theodore" last="Benice">Theodore Benice</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
<placeName>
<region type="state">Oregon</region>
<settlement type="city">Portland</settlement>
</placeName>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
</affiliation>
</author>
<author>
<name sortKey="Oken, Barry" sort="Oken, Barry" uniqKey="Oken B" first="Barry" last="Oken">Barry Oken</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
<placeName>
<region type="state">Oregon</region>
<settlement type="city">Portland</settlement>
</placeName>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
</affiliation>
</author>
<author>
<name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>General Clinical Research Center, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
<placeName>
<region type="state">Oregon</region>
<settlement type="city">Portland</settlement>
</placeName>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
</affiliation>
</author>
<author>
<name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
<placeName>
<region type="state">Oregon</region>
<settlement type="city">Portland</settlement>
</placeName>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-10">2003-10</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1108">1108</biblScope>
<biblScope unit="page" to="1114">1114</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9F3A0B88BDBDA778663C8133C5FE3B60024071E5</idno>
<idno type="DOI">10.1002/mds.10505</idno>
<idno type="ArticleID">MDS10505</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Carbidopa</term>
<term>Chemotherapy</term>
<term>Cross-Over Studies</term>
<term>Crossover study</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Double blind study</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Drug combination</term>
<term>Fatigue</term>
<term>Fatigue (drug therapy)</term>
<term>Fatigue (etiology)</term>
<term>Female</term>
<term>Fingers (physiology)</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>MFI</term>
<term>MIDI</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Movement (drug effects)</term>
<term>Muscle Contraction (drug effects)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prognosis</term>
<term>Psychomotor Performance (drug effects)</term>
<term>Questionnaires</term>
<term>Regression Analysis</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>finger tapping</term>
<term>force generation</term>
<term>physical fatigue</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Motor Activity</term>
<term>Movement</term>
<term>Muscle Contraction</term>
<term>Psychomotor Performance</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Fatigue</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Fatigue</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Fingers</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Regression Analysis</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Adulte</term>
<term>Association médicamenteuse</term>
<term>Carbidopa</term>
<term>Chimiothérapie</term>
<term>Essai croisé</term>
<term>Etude double insu</term>
<term>Fatigue</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Pronostic</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Adulte</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Visit 1 or 2 and participated in the following two studies: (1) Finger tapping. Twenty‐five PD patients used their index fingers to strike two keys 20 cm apart on a musical instrument digital interface (MIDI) keyboard. The slopes of the regression line of dwell time and movement time were used to assess the rate of fatigue development. (2) Force generation. Twelve PD patients contracted the wrist extensors maximally to obtain a baseline maximum voluntary contraction (BMVC) force. Then they repetitively contracted the wrist extensors at 50% of the BMVC for 7 seconds and rested for 3 seconds. An interval maximum voluntary contraction (IMVC) was measured every three repetitions. Fatigue was defined as an IMVC of less than 60% of the BMVC. The slope of the regression line of IMVC was used to assess the rate of force decline. These two studies were repeated 1 hour after carbidopa/levodopa (25/100) or placebo. Subjects filled out the Multidimensional Fatigue Inventory (MFI) at the beginning of the first visit. Results showed that the slope of dwell time decreased with levodopa but not with placebo (P = 0.004). The rate of force decline also decreased with levodopa but not with placebo (P = 0.01). The subscores in the dimension of physical fatigue in the MFI did not correlate with the rate changes in dwell time or the rate changes in force decline. We concluded that (1) levodopa improves physical fatigue in finger tapping and force generation, (2) physical fatigue in Parkinson's disease is at least partially related to dopamine deficiency, and (3) the MFI measures different aspects of physical fatigue compared with those measured by finger tapping and force generation. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Oregon</li>
</region>
<settlement>
<li>Portland</li>
</settlement>
<orgName>
<li>Université des sciences et de la médecine de l'Oregon</li>
</orgName>
</list>
<tree>
<country name="États-Unis">
<region name="Oregon">
<name sortKey="Lou, Jau Hin" sort="Lou, Jau Hin" uniqKey="Lou J" first="Jau-Shin" last="Lou">Jau-Shin Lou</name>
</region>
<name sortKey="Benice, Theodore" sort="Benice, Theodore" uniqKey="Benice T" first="Theodore" last="Benice">Theodore Benice</name>
<name sortKey="Kearns, Greg" sort="Kearns, Greg" uniqKey="Kearns G" first="Greg" last="Kearns">Greg Kearns</name>
<name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
<name sortKey="Oken, Barry" sort="Oken, Barry" uniqKey="Oken B" first="Barry" last="Oken">Barry Oken</name>
<name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004053 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004053 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:9F3A0B88BDBDA778663C8133C5FE3B60024071E5
   |texte=   Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024